Literature DB >> 2695927

Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli.

J E Strickler1, J Gorniak, B Dayton, T Meek, M Moore, V Magaard, J Malinowski, C Debouck.   

Abstract

A recombinant plasmid encompassing the human immunodeficiency virus type 1 (HIV 1) protease coding sequence and flanking regions (Ala-13 to Gly-185 of the pol open reading frame) has been expressed in two distinct strains of Escherichia coli, AR58 and AR68. In the first strain, AR58, the primary translation product, a 25 kilodalton (kDa) precursor protein, is short-lived and rapidly processes itself to the 11 kDa mature protease in vivo. In the second strain, AR68, the 25 kDa species is only partially processed, and it, a 13 kDa intermediate, and the mature 11 kDa enzyme accumulate at a ratio of 3:4.5:2.5, respectively. The 11 kDa mature protease from AR58 and the 25 kDa precursor from AR68 have been purified to homogeneity. The yield of 11 kDa enzyme from AR58 is approximately 0.02 mg/g wet weight of E. coli cell pellet. The protease has both the expected NH2- and COOH-terminal sequences. The yield of 25 kDa enzyme from AR68 is approximately 0.1 mg/g wet weight of E. coli cell pellet. In vitro, the 25 kDa precursor enzyme rapidly (t1/2 approximately equal to 9 min) processes itself into a species with a mass of approximately 13 kDa and a species with a mass of approximately 11 kDa. Both of these latter species can be separated by RP-HPLC, have the NH2-terminal sequence expected for the mature protease, and are active. The 11 kDa enzyme from AR58 comigrates with the 11 kDa enzyme from AR68 on RP-HPLC and SDS polyacrylamide gel electrophoresis. On extended incubation at 4 degrees C at either neutral or acidic pH all species of the protein exhibit further autodegradation at defined sequences. The availability of the mature, 11 kDa enzyme and the 25 kDa precursor will allow biochemical and physical studies on this critical viral enzyme.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2695927     DOI: 10.1002/prot.340060205

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  6 in total

1.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  HIV-I protease. Cloning, expression, and purification.

Authors:  N I Dergousova; A M Volynskaya; L D Rumsh
Journal:  Appl Biochem Biotechnol       Date:  1996 Oct-Nov       Impact factor: 2.926

3.  Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain.

Authors:  G Zybarth; H G Kräusslich; K Partin; C Carter
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

4.  Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies.

Authors:  J O Hui; A G Tomasselli; I M Reardon; J M Lull; D P Brunner; C S Tomich; R L Heinrikson
Journal:  J Protein Chem       Date:  1993-06

5.  Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.

Authors:  David A Davis; Irene R Tebbs; Sarah I Daniels; Stephen J Stahl; Joshua D Kaufman; Paul Wingfield; Michael J Bowman; Jean Chmielewski; Robert Yarchoan
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

6.  Gag-Pol processing during HIV-1 virion maturation: a systems biology approach.

Authors:  Balázs Könnyű; S Kashif Sadiq; Tamás Turányi; Rita Hírmondó; Barbara Müller; Hans-Georg Kräusslich; Peter V Coveney; Viktor Müller
Journal:  PLoS Comput Biol       Date:  2013-06-06       Impact factor: 4.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.